Telesis Bio has entered into a licensing agreement with Regeneron Pharmaceuticals to integrate its Gibson SOLA platform within the latter’s research and development (R&D) facilities.
This deal allows Regeneron to utilise Telesis Bio’s automated platform for on-demand, high-throughput DNA and gene synthesis.
The Gibson SOLA platform is a reagent-based system featuring a suite of software tools that can be integrated at various scales and throughput levels. It enables users to take full control of their nucleic acid production, from initial design to final molecule synthesis, without relying on external supply chains.
The system maintains data security and privacy for clients while providing flexibility through compatibility with standard liquid-handling automation solutions.
It is designed to facilitate rapid, on-site synthesis of DNA and mRNA, reducing design-to-build timelines significantly. This capability enables researchers to streamline workflows, maintain tighter intellectual property control, and decrease reliance on external providers.
Telesis Bio CEO Eric Esser said: “Regeneron is one of the most forward-thinking biotechnology companies and is known for pushing the boundaries of scientific discovery and accelerating drug development.
“Adopting the Gibson SOLA platform is intended to enable full control of the nucleic acid supply-chain and allows Regeneron to gain new insights that can aid in drug development.”
The Gibson SOLA platform is designed to be adaptable across various scales and throughput levels, allowing flexibility in laboratory settings. It supports applications in biologics, vaccines, and cell and gene therapy by enabling high-fidelity and high-purity nucleic acid synthesis.
This technology is said to eliminate the need for traditional cloning methods and improves operational efficiency.
In March 2025, Telesis Bio secured a convertible preferred stock purchase agreement, anticipated to raise around $21m. Led by Novalis LifeSciences and Northpond Ventures, this financing underpins the continued development of the Gibson SOLA platform.
